دورية أكاديمية
أعرض في EDS

A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol.

التفاصيل البيبلوغرافية
العنوان: A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol.
المؤلفون: Xie W; Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015 Beijing, China., Shi G; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China., Zhang H; Department of Pediatric Hepatology, The 302 Hospital of PLA, Beijing, China., Zhao G; Department of Hepatology, Tianjin Municipal Hospital of Infectious Diseases, Tianjin, China., Yu Z; Department of Infectious Diseases, First Hospital, Zhengzhou University, Zhengzhou, China., Lang Z; Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015 Beijing, China., Zhao H; Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015 Beijing, China., Yan J; Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015 Beijing, China., Cheng J; Liver Center, Beijing Ditan Hospital, Capital Medical University, 100015 Beijing, China.
المصدر: Hepatology international [Hepatol Int] 2011 Jul 20; Vol. 6 (2), pp. 441-448. Date of Electronic Publication: 2011 Jul 20 (Print Publication: 2012).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: eCollection Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Springer
مستخلص: Objective: To evaluate the efficacy and safety profiles of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated with adefovir dipivoxil (ADV) or ADV plus bicyclol, and to optimize the treatment strategy for CHB patients.
Patients and Methods: A total of 250 patients with HBeAg-positive CHB were randomized to ADV plus bicyclol combination group and ADV monotherapy group. The patients in the ADV plus bicyclol combination therapy group ( n  = 125) received ADV 10 mg orally q.d. and bicyclol 25 mg orally t.i.d. for 48 weeks, and those in the ADV monotherapy group ( n  = 125) were administered ADV 10 mg orally q.d. alone for 48 weeks. The serum aminotransferases (ALT/AST), HBV DNA, HBeAg/HBeAb, and liver biopsy were conducted before and after therapy.
Results: The serum aminotransferase levels were decreased significantly in both groups. The serum aminotransferase level in ADV plus bicyclol combination therapy group decreased greater than that in ADV monotherapy group ( P  < 0.01). The virological response rate in ADV plus bicyclol combination therapy group was not significantly different from that in ADV monotherapy group ( P  > 0.05). After treatment for 48 weeks, the Knodell necroinflammatory score of the two groups were all alleviated significantly, and the Knodell score in the combination group was significantly lower than that in the ADV monotherapy group ( P  < 0.05). There were no remarkable adverse events probably related to the drug in this study.
Conclusion: Adefovir dipivoxil plus bicyclol combination therapy is a safe and superior treatment regimen for patients with HBeAg-positive CHB when compared with ADV monotherapy.
References: J Natl Cancer Inst. 2009 Aug 5;101(15):1066-82. (PMID: 19574418)
J Interferon Cytokine Res. 2010 Dec;30(12):901-8. (PMID: 20973680)
Mol Pharmacol. 2009 May;75(5):1180-8. (PMID: 19188336)
J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. (PMID: 20659226)
Drug Dev Ind Pharm. 2009 Nov;35(11):1348-55. (PMID: 19832635)
Eur J Gastroenterol Hepatol. 2001 Dec;13(12):1499-506. (PMID: 11742201)
N Engl J Med. 2005 Jun 30;352(26):2673-81. (PMID: 15987916)
Hepatology. 2006 Jul;44(1):108-16. (PMID: 16799983)
Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):300-5. (PMID: 19210495)
Postgrad Med. 2010 Sep;122(5):165-75. (PMID: 20861600)
J Viral Hepat. 2010 Feb 1;17(2):115-22. (PMID: 19874478)
Pharmazie. 2010 Mar;65(3):206-12. (PMID: 20383942)
Hepatology. 1981 Sep-Oct;1(5):431-5. (PMID: 7308988)
J Asian Nat Prod Res. 2010 Apr;12(4):313-23. (PMID: 20419542)
Liver Int. 2005 Aug;25(4):872-9. (PMID: 15998439)
Med Chem. 2009 Jan;5(1):29-43. (PMID: 19149648)
N Engl J Med. 2003 Feb 27;348(9):808-16. (PMID: 12606735)
J Med Virol. 2010 Nov;82(11):1835-42. (PMID: 20872709)
J Asian Nat Prod Res. 2009 Jun;11(6):576-83. (PMID: 20183293)
Acta Pharmacol Sin. 2010 Feb;31(2):219-26. (PMID: 20139905)
Hepatology. 2007 Feb;45(2):507-39. (PMID: 17256718)
Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1290-6. (PMID: 20964259)
J Hepatol. 2010 Aug;53(2):261-6. (PMID: 20466447)
J Viral Hepat. 2005 Jan;12(1):67-73. (PMID: 15655050)
Value Health. 2010 Dec;13(8):922-33. (PMID: 20825619)
Aliment Pharmacol Ther. 2011 Jan;33(1):127-37. (PMID: 21083592)
Hepatology. 2003 Dec;38(6):1419-27. (PMID: 14647053)
J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S158-68. (PMID: 15602165)
Hepatology. 2010 Sep;52(3):886-93. (PMID: 20683932)
Hepatol Int. 2008 Sep;2(3):284-95. (PMID: 19669256)
World J Gastroenterol. 2004 Jun 15;10(12):1775-9. (PMID: 15188504)
فهرسة مساهمة: Keywords: Adefovir dipivoxil; Bicyclol; Chronic hepatitis B
تواريخ الأحداث: Date Created: 20110721 Latest Revision: 20211020
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3314819
DOI: 10.1007/s12072-011-9294-7
PMID: 21773778
قاعدة البيانات: MEDLINE
الوصف
تدمد:1936-0541
DOI:10.1007/s12072-011-9294-7